Weekly Research Analysts’ Ratings Changes for Neurocrine Biosciences (NBIX)

A number of firms have modified their ratings and price targets on shares of Neurocrine Biosciences (NASDAQ: NBIX) recently:

• 8/4/2026 – Neurocrine Biosciences was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/3/2026 – Neurocrine Biosciences had its price target raised by Canaccord Genuity Group Inc. from $200.00 to $210.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Neurocrine Biosciences had its price target raised by Truist Financial Corporation from $200.00 to $213.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Neurocrine Biosciences had its price target raised by Wedbush from $185.00 to $194.00. They now have an “outperform” rating on the stock.
• 8/1/2026 – Neurocrine Biosciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Citigroup Inc. from $246.00 to $249.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $195.00 to $198.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $193.00 to $196.00. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by TD Cowen from $200.00 to $220.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Cantor Fitzgerald from $210.00 to $215.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Piper Sandler from $207.00 to $210.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Stifel Nicolaus from $188.00 to $215.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $200.00 to $222.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Neurocrine Biosciences had its price target raised by Needham & Company LLC from $200.00 to $204.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 7/21/2026 – Neurocrine Biosciences had its price target raised by Guggenheim from $175.00 to $200.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Neurocrine Biosciences had its price target raised by Wells Fargo & Company from $175.00 to $200.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Neurocrine Biosciences had its price target raised by Truist Financial Corporation from $155.00 to $200.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Neurocrine Biosciences had its price target raised by BMO Capital Markets from $144.00 to $170.00. They now have a “market perform” rating on the stock.
• 7/10/2026 – Neurocrine Biosciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 7/7/2026 – Neurocrine Biosciences had its price target raised by Royal Bank Of Canada from $183.00 to $195.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Neurocrine Biosciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 6/23/2026 – Neurocrine Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the transaction, the director directly owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This trade represents a 32.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at $2,621,975.20. The trade was a 61.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 395,422 shares of company stock worth $62,448,693. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.